Purchase this article with an account.
A.E. Partal, E.E. Manche; Analysis of the efficacy, predictability, and safety of CustumVue LASIK for myopia and myopic astigmatism using the VISX S4 excimer laser . Invest. Ophthalmol. Vis. Sci. 2004;45(13):206.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the efficacy, predictability, and safety of custom LASIK using the CustomVue wavefront technology for the treatment of myopia and myopic astigmatism. Methods: Retrospective analysis of 159 eyes of 85 patients that underwent CustomVue LASIK for myopia using the VISX Star S4 excimer laser. Results: UCVA at 1 month was 20/40 or better in 99.4% and 20/20 or better in 85.5% of eyes. UCVA at 3 months was 20/40 or better in 100% of eyes and 20/20 or better in 88%. In addition, at 1 month, the spherical equivalent was within +/– 0.5 D of emmetropia in 91.8% and within +/– 1 D in 100% of eyes. Similarly, at 3 months, the spherical equivalent was within +/– 0.5 D of emmetropia in 78% of eyes, and within +/– 1D in 100% of eyes. No eyes lost two or more lines of BSCVA. Patients reported that they were very happy with their quality of vision. Conclusions: Preliminary data suggest that CustomVue LASIK is an effective, predictable, and safe procedure. Six month follow–up data will be available and presented.
This PDF is available to Subscribers Only